clofibrate has been researched along with angiotensin i in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cervantes-Pérez, LG; Del Valle-Mondragón, L; Ibarra-Lara, L; Oidor-Chan, VH; Pastelín-Hernández, GS; Pérez-Severiano, F; Ramírez-Ortega, M; Sánchez-Aguilar, M; Sánchez-Mendoza, A; Soria-Castro, E; Torres-Narváez, JC; Zarco-Olvera, G | 1 |
1 other study(ies) available for clofibrate and angiotensin i
| Article | Year |
|---|---|
Peroxisome proliferator-activated receptor-α stimulation by clofibrate favors an antioxidant and vasodilator environment in a stressed left ventricle.
Topics: Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme 2; Animals; Antioxidants; Aortic Coarctation; Captopril; Catalase; Clofibrate; Drug Synergism; Heart Ventricles; Hypertension; Lipid Peroxidation; Male; Nitric Oxide Synthase Type III; Oxidative Stress; Peptide Fragments; Peptidyl-Dipeptidase A; PPAR alpha; Proto-Oncogene Mas; Proto-Oncogene Proteins; Rats; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, G-Protein-Coupled; Renin-Angiotensin System; Superoxide Dismutase; Vasodilation | 2016 |